Skip to main content

Table 3 Decrease of RF titers in adalimumab treated patients: correlation with the clinical response to treatment

From: Adalimumab clinical efficacy is associated with rheumatoid factor and anti-cyclic citrullinated peptide antibody titer reduction: a one-year prospective study

ACR response, week 24

Week 0

Week 24

P

ACR response, week 48

Week 0

Week 48

P

<20% (n = 6)

130.5 ± 97.9

116.5 ± 88.6

n.s.

<20% (n = 3)

89 ± 73

60.3 ± 49.2

n.d.

ACR 20 (n = 22)

155.3 ± 147.5

109 ± 123

<0.0001

ACR 20 (n = 23)

164.5 ± 141.3

105.7 ± 112.6

<0.0001

ACR 50 (n = 21)

94.1 ± 60.9

57.3 ± 36.2

<0.0001

ACR 50 (n = 16)

96.4 ± 73.2

51.6 ± 41

0.0001

ACR 70 (n = 8)

94.8 ± 164.2

40.4 ± 54

n.s.

ACR 70 (n = 15)

89.5 ± 123.4

37.5 ± 40.7

0.018

  1. Results are means ± SD. ACR, American College of Rheumatology; n.d., not done; n.s., not significant; RF, rheumatoid factor.